Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
AUTOR(ES)
Axworthy, D. B.
FONTE
The National Academy of Sciences
RESUMO
A covalent conjugate (NR-LU-10/SA) was prepared between streptavidin (SA) and NR-LU-10, a mAb that binds an antigen expressed on the surface of most human carcinomas. NR-LU-10/SA was injected into nude mice bearing human tumor xenografts. Injection of biotinylated galactosyl-human serum albumin reduced the circulating levels of conjugate by 95%. Subsequent administration of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-biotin achieved peak uptake at the tumor within 2 hr while >80% of the radioactivity was eliminated in the urine. A single dose of 600–800 μCi of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-biotin produced cures in 10/10 mice with established (>200 mm3) s.c. human small cell lung or colon cancer xenografts and 8/10 cures in mice with human breast cancer xenografts without significant toxicity.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=26516Documentos Relacionados
- Long term follow up of radiosynovectomy with yttrium-90 silicate in haemophilic haemarthrosis.
- Comparison of two yttrium-90 regimens in inflammatory and osteoarthropathies.
- Radioactivity studies on 2 synovial specimens after radiation synovectomy with yttrium-90 silicate.
- Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts
- Listeria monocytogenes septic arthritis following intra-articular yttrium-90 therapy.
